Mammals aren’t known for the ocular regenerative powers, but a new study shows that nature has a few tricks up its sleeve.

BOSTON, MA, UNITED STATES, January 8, 2026 /EINPresswire.com/ -- EyeCool Therapeutics, a clinical-stage ophthalmic ...

Signs and symptoms of ocular surface disease could be significantly reduced within 4 days after treatment with shelf-stable ...

Conjunctivitis or episcleritis and scleritis comprised the most common eye manifestations, while cataracts (11.7%) and visual ...

Ocular Therapeutix is nearing the completion of a head-to-head clinical trial that could be key for the company, investors, ...

Discover how cardiovascular risk scores can indicate future eye disease risk. Keep reading to learn how to protect vision.

Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-201 data from the first cohort in mid-2026 –-- ...

If you are wondering whether Ocular Therapeutix at around US$11.25 still offers value or if most of the opportunity is already priced in, you are asking the right question. The stock has been volatile ...

Ocular Therapeutix Inc. (NASDAQ:OCUL) is one of the low priced stocks to buy with high upside potential. On December 12, Bank ...

Ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) reported Q3 CY2025 results , but sales fell by 5.7% ...